Tags

Type your tag names separated by a space and hit enter

A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.
Am J Case Rep. 2021 Jul 21; 22:e931478.AJ

Abstract

BACKGROUND Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient's hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding.

Authors+Show Affiliations

Department of Family Medicine, Ascension Providence Rochester Hospital, Rochester, MI, USA.Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI, USA.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

34285180

Citation

King, Eleanor R., and Elizabeth Towner. "A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination." The American Journal of Case Reports, vol. 22, 2021, pp. e931478.
King ER, Towner E. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. Am J Case Rep. 2021;22:e931478.
King, E. R., & Towner, E. (2021). A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. The American Journal of Case Reports, 22, e931478. https://doi.org/10.12659/AJCR.931478
King ER, Towner E. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. Am J Case Rep. 2021 Jul 21;22:e931478. PubMed PMID: 34285180.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. AU - King,Eleanor R, AU - Towner,Elizabeth, Y1 - 2021/07/21/ PY - 2021/7/21/entrez PY - 2021/7/22/pubmed PY - 2021/7/23/medline SP - e931478 EP - e931478 JF - The American journal of case reports JO - Am J Case Rep VL - 22 N2 - BACKGROUND Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient's hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding. SN - 1941-5923 UR - https://www.unboundmedicine.com/medline/citation/34285180/A_Case_of_Immune_Thrombocytopenia_After_BNT162b2_mRNA_COVID-19_Vaccination. L2 - https://www.amjcaserep.com/download/index/idArt/931478 DB - PRIME DP - Unbound Medicine ER -